ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an inve… Read more
Market Cap & Net Worth: ContraFect Corporation (CFRXQ)
ContraFect Corporation (PINK:CFRXQ) has a market capitalization of $2.14K ($2.14K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #50068 globally and #15276 in its home market, demonstrating a 100.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ContraFect Corporation's stock price $0.00 by its total outstanding shares 10704803 (10.70 Million).
ContraFect Corporation Market Cap History: 2023 to 2025
ContraFect Corporation's market capitalization history from 2023 to 2025. Data shows growth from $321.14K to $2.14K (0.00% CAGR).
ContraFect Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ContraFect Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CFRXQ by Market Capitalization
Companies near ContraFect Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to ContraFect Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ContraFect Corporation Historical Marketcap From 2023 to 2025
Between 2023 and today, ContraFect Corporation's market cap moved from $321.14K to $ 2.14K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.14K | +100.00% |
| 2024 | $1.07K | -99.67% |
| 2023 | $321.14K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ContraFect Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.14K USD |
| MoneyControl | $2.14K USD |
| MarketWatch | $2.14K USD |
| marketcap.company | $2.14K USD |
| Reuters | $2.14K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.